Phase Genomics
TypeStartup company
IndustryBiotechnology
Founded2015
FoundersIvan Liachko, Shawn Sullivan
Headquarters
Seattle, Washington, US
Key people
Ivan Liachko (CEO, president), Shawn Sullivan (CTO)
Websitephasegenomics.com

Phase Genomics is an American biotechnology company based in Seattle, Washington. The company develops proximity ligation kits and Hi-C sequencing technology used to analyze chromosomes. Phase Genomics sells proximity ligation kits, scientific services, and computational analyses.

History

The company was founded by Ivan Liachko and Shawn Sullivan in 2015. It was originally housed in the CoMotion biotech incubator at University of Washington before relocating to a separate facility. It develops proximity ligation kits and Hi-C sequencing technology used to analyze chromosomes. The company sells proximity ligation kits, scientific services, and computational analyses.[1]

Research

Phase Genomics developed a library preparation kit for the Hi-C sequencing method previously developed by researchers Job Dekker and Eric Lander. The kits are used to study the architecture of genomes.[2] In 2018, Phase Genomics received a $1.5 million SBIR grant from the National Institute of Allergy and Infectious Diseases (NIAID) to research antimicrobial resistance using Hi-C technology. In January 2020, it was awarded an additional $1.5 million from NIAID for phase 2 SBIR funding.[3] In 2019, Phase Genomics received $200,000 from the Bill & Melinda Gates Foundation to improve computational methods of extracting genomic data in microbiome samples.[3][4] Later in 2019, the company was awarded $325,000 from the U.S. Department of Energy to research algae biofuels using proximity litigation technology for metagenome assembly.[4] In 2020, Phase Genomics received 2 grants totaling $3.9 million from the National Human Genome Research Institute and the Eunice Kennedy Shriver National Institute of Child Health and Human Development. The 3-year grants fund research on chromosomal abnormalities causing cancer, infertility, and reproductive issues.[1]

In June 2021, the company released a platform for discovering new viruses in microbiome samples.[5][6]

References

  1. 1 2 Stiffler, Lisa (September 30, 2020). "Phase Genomics lands $3.9M in grants to improve testing for chromosomal abnormalities". GeekWire. Retrieved January 31, 2021.
  2. ↑ LeMieux, Julianna (November 15, 2018). "Precision Medicine Looks beyond DNA Sequences". Genetic Engineering & Biotechnology News. 38 (20): 1, 22, 24–25. doi:10.1089/gen.38.20.02. ISSN 1935-472X. S2CID 239781336.
  3. 1 2 "Phase Genomics Wins $1.5M for Proximity Ligation-Based AMR Tracking". GenomeWeb. January 7, 2020. Retrieved January 31, 2021.
  4. 1 2 Kotrba, Ron (October 22, 2019). "Phase Genomics awarded DOE grant for algae biofuel research". Biodiesel Magazine. Retrieved January 31, 2021.
  5. ↑ Gounot, Jean-Sebastien; Chia, Minghao; Bertrand, Denis; Saw, Woei-Yuh; Ravikrishnan, Aarthi; Low, Adrian; Ding, Yichen; Ng, Amanda Hui Qi; Tan, Linda Wei Lin; Teo, Yik-Ying; Seedorf, Henning; Nagarajan, Niranjan (October 13, 2022). "Genome-centric analysis of short and long read metagenomes reveals uncharacterized microbiome diversity in Southeast Asians". Nature Communications. 13 (1): 6044. Bibcode:2022NatCo..13.6044G. doi:10.1038/s41467-022-33782-z. ISSN 2041-1723. PMC 9561172. PMID 36229545.
  6. ↑ "Phase Genomics Releases Platform for Discovering New Viruses in Microbiome Samples". www.businesswire.com. June 15, 2021. Retrieved December 7, 2022.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.